ThermoGenesis (NASDAQ:THMO) is a global life sciences company specializing in automated cell processing and liquid handling solutions designed to support the manufacturing and application of advanced cellular therapies. Its core product lines include the Sepax® family of automated cell separation systems, ThawSTAR® controlled-rate cell thawing platforms, and Visio® sample management systems for high-throughput cryogenic storage. These integrated technologies enable biopharma companies, academic institutions and cord blood banks to streamline workflow, improve reproducibility and maintain regulatory compliance throughout the cell therapy development process.
Since its founding in 2008, ThermoGenesis has focused on bridging gaps in the cell therapy value chain by delivering end-to-end automation solutions. The company’s instruments are used in autologous and allogeneic settings for hematopoietic stem cell transplantation, immuno-oncology applications and regenerative medicine. By standardizing critical steps such as cell isolation, washing, freezing and thawing, ThermoGenesis products reduce manual interventions, minimize the risk of contamination and support scalable commercialization of next-generation therapies.
Headquartered in Irvine, California, ThermoGenesis maintains a direct presence in North America, Europe and Asia-Pacific through a combination of owned offices and distribution partners. Over the years, the company has secured multiple regulatory clearances and built strategic alliances with leading biopharmaceutical firms, contract manufacturing organizations and research centers. Its robust global service network provides training, validation support and after-sales maintenance to ensure uninterrupted operation in clinical and manufacturing environments.
ThermoGenesis is guided by a management team with deep expertise in biotechnology, medical devices and cell therapy manufacturing. Under the leadership of its chief executive officer and board of directors, the company continues to invest in research and development to expand its product portfolio and address emerging needs in personalized medicine. Through ongoing innovation and collaboration, ThermoGenesis aims to accelerate the translation of cell-based treatments from laboratory to bedside.
